Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Unmet need for prophylactic and therapeutic HSV vaccines remains high as genital herpes prevalence rises, says GlobalData

GSK has recently announced its decision to halt development of its herpes simplex virus (HSV) therapeutic vaccine candidate, GSK3943104, which was under investigation for genital herpes, after a Phase I/II clinical trial failed to meet its primary efficacy goals. The vaccine was not associated with any safety concerns in the trial. However, owing to the […]
Read more

Atopic Dermatitis: A hotspot for innovation and investment opportunities, says GlobalData

Atopic dermatitis (AD) is emerging as a dynamic field ripe with innovation and investment opportunities. With the market projected to reach $16.7 billion by 2030 across the seven major markets (7MM*), driven by rising prevalence and advancements in treatment, pharmaceutical companies are increasingly focusing on novel therapies. This sector promises substantial growth as new treatments […]
Read more

Radiopharmaceuticals for prostate cancer to go nuclear with $6.3 billion in sales by 2030, forecasts GlobalData

Radioligand therapies (RLTs) have received prominent attention from major pharmaceutical companies in treating prostate cancer. Bayer’s Xofigo (radium-223 dichloride) demonstrated the proof-of-concept with its FDA approval for castration-resistant prostate cancer (CRPC). Interest in RLTs has since peaked, with Novartis acquiring developer Advanced Accelerator Applications and the highly effective Pluvicto (lutetium [177Lu] vipivotide tetraxetan), targeting prostate-specific […]
Read more

Takeda and Astellas key firms in advancing early gene therapy research in Japan, reveals GlobalData

The gene therapy research in Japan has gained significant momentum due to the SAKIGAKE designation system and government-led initiatives like the “Project for Regenerative/Cellular Medicine and Gene Therapies” to accelerate research and development (R&D) to create new technologies for gene/cell therapy. In advancing early gene therapy research in Japan, Takeda and Astellas currently stand as […]
Read more

World Sepsis Day 2024: Improved clinical trial design and targeted therapies remain key unmet needs, says GlobalData

World Sepsis Day, which takes place annually on September 13, aims to raise awareness of the devastating condition that claims millions of lives globally each year. Sepsis is a life-threatening and complex disease caused by a dysregulated host immune response to an infection. Currently, there is no drug that specifically targets the underlying pathophysiological processes […]
Read more

Dupert offers new hope for advanced NSCLC patients as China’s first KRAS G12C Inhibitor, says GlobalData

GenFleet Therapeutics and Innovent Biologics have secured approval from China’s National Medical Products Administration (NMPA) for Dupert (fulzerasib), the country’s first KRAS G12C inhibitor for advanced non-small cell lung cancer (NSCLC) in adults who have undergone prior systemic therapy. This breakthrough therapy addresses a challenging mutation, offering a critical new treatment option for patients with […]
Read more

WHO’s mpox response plan provides direction for coordinated response to reduce disease burden, says GlobalData

In response to the mpox outbreak in Africa, the World Health Organization (WHO) has launched an international Strategic Preparedness and Response Plan (SPRP) and hosted a research response conference whereby researchers, public health officials, and stakeholders from affected countries were invited to take the lead in shaping research efforts and aligning them with outbreak response […]
Read more

IASP World Congress highlights need for unified guidelines on opioid use in chronic pain, says GlobalData

At the recently held International Association for the Study of Pain (IASP) World Congress, a presentation during a topical workshop revealed significant discrepancies in clinical practice guidelines (CPGs) across countries for opioid use in chronic pain management. The inconsistencies raise concerns about the role of CPGs in the overprescription of opioids, potentially exacerbating the risk […]
Read more

Abaloparatide approval to enhance osteoporosis treatment landscape for high-risk patients in UK, says GlobalData

The National Institute for Health and Care Excellence (NICE) approved abaloparatide for treating patients at high risk of fractures in the UK, providing a new and effective treatment option for severe osteoporosis. This approval marks a critical milestone in improving patient outcomes and broadening therapeutic choices in the UK’s osteoporosis market, according to GlobalData, a […]
Read more

Rising ADHD diagnoses in 7MM linked to standardized screening tools and guidelines, says GlobalData

The increase in attention-deficit/hyperactivity disorder (ADHD) diagnoses across the seven major markets (7MM*) is closely tied to the adoption of standardized screening tools and updated clinical guidelines. These developments, particularly in the US, have led to more accurate identification of ADHD cases, especially among adults, helping to address the disorder’s significant socioeconomic and mental health […]
Read more

rVSV-ZEBOV vaccine first real-world data support prophylactic use for future Ebola outbreaks, says GlobalData

The rVSV-ZEBOV vaccine has demonstrated real-world effectiveness of approximately 84% against Ebola virus disease, revealed a recent study carried out by researchers in Europe and the Democratic Republic of the Congo (DRC). This retrospective, test-negative study, which analyzed 618 individuals during the 2018-2020 Ebola virus epidemic in the DRC, supports the prophylactic use of rVSV-ZEBOV […]
Read more

China pharma firms eye stronghold in therapeutic cancer vaccines market, says GlobalData

Cancer vaccines represent a burgeoning field in oncology, with the potential to revolutionize cancer treatment. Earlier, approved cancer vaccines were prophylactic against cancer-causing viruses. However, recent advancements have shifted towards developing therapeutic cancer vaccines, which focus on identifying tumor-specific antigens to create innovative cancer immunotherapies. In this context, Chinese companies are actively positioning themselves to […]
Read more

Gilead’s Livdelzi wins FDA approval, challenges Ocaliva dominance in primary biliary cholangitis market, says GlobalData

Gilead Sciences has recently announced the US FDA’s approval of seladelpar, its PPAR-δ agonist, under the brand name Livdelzi, for primary biliary cholangitis (PBC). This major turnaround for seladelpar, once a failed non-alcoholic steatohepatitis (NASH) asset, follows Gilead’s acquisition of the asset’s developer, Cymabay Therapeutics, earlier this year. The approval could present a major challenge […]
Read more

GLP-1R market: A two horse race, says GlobalData

The popularity of glucagon-like peptide-1 receptor (GLP-1R) drugs has exploded in recent years due to their abilities in effectively treating metabolic-related disorders such as obesity and type 2 diabetes. As obesity rates rise and trust in GLP-1R products grows, sales for drugs targeting this receptor are forecast to increase fourfold to an estimated $142 billion […]
Read more

Pharma CMO M&A activity shifts focus to scaling in 2023, reveals GlobalData

Merger and acquisition (M&A) activity in the pharmaceutical contract manufacturing industry declined in 2023 compared to 2021-22. High inflation and interest rates along with an uncertain business environment disincentivized investment. Despite fewer deals, the focus shifted towards scaling operations rather than acquiring specialized capabilities, according to GlobalData, a leading data and analytics company. Adam Bradbury, […]
Read more

Scholar Rock’s apitegromab holds potential to become first myostatin inhibitor for SMA patients, says GlobalData

As part of its Q2 2024 Financial Results and Business Progress reporting, Scholar Rock disclosed new positive data from its Phase II TOPAZ trial, with results showing continued and sustained motor function over four years in non-ambulatory patients with spinal muscular atrophy (SMA) treated with apitegromab and nusinersen. The positive data lays the foundation for […]
Read more

Atopic dermatitis treatment sees promising future with new drug approvals, says GlobalData

Atopic dermatitis (AD) is experiencing a transformative shift in treatment management with recent drug approvals that address critical unmet needs. The introduction of novel therapies, such as Dermavant’s VTAMA (tapinarof) (Japan) and Arcutis’s ZORYVE (roflumilast) (US), with innovative mechanisms of action, offers hope for improved patient outcomes. As these treatments enter the market, they underscore […]
Read more
1 … 16 17 18 19 20 … 110